



PARENTERAL DRUGS (INDIA) LTD.



"Speed-post"

Date: 11th November, 2010

To
National Stock Exchange of India Limited
Exchange Plaza,
Plot No.C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai-400 051

Sub: Submission of Unaudited Financial Results for the quarter ended 30th
September, 2010


Dear Sir,

Please find enclosed Unaudited Consolidated as well as Standalone Financial results for the quarter ended on 30th September, 2010 alongwith Standalone and Consolidated Statement of Assets and Liabilities.

This is for the information of the Exchange and members thereof.

You are requested to take the same on record.

Thanking You
Yours Sincerely
For Parenteral Drugs (India) Limited


Archana Agar
Company Secretary

Encl.: a/a

PARENTERAL DRUGS (INDIA) LIMITED
REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053


UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED ON 30TH SEPT, 2010

STANDALONE				(Rs. In Lacs)	
Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the previous period	For the Year ended
	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	31-03-2010 (Audited)
Net Sales/ Income from Operations	13159.76	8901.14	23034.67	16425.85	33728.21
Other operating Income	12.96	28.63	29.68	50.21	133.88
Total Income	13172.72	8929.77	23064.35	16476.06	33862.09
Expenditure					
- Increase / Decrease in stock in trade and work in progress	-432.30	256.18	-481.27	-453.73	18.69
- Consumption of raw materials	6579.88	4420.51	11319.84	8809.81	18483.22
- Employees cost	364.41	305.96	722.05	592.74	1073.34
- Depreciation	197.00	145.00	394.00	290.00	766.61
- Other Expenditure	3941.95	2383.54	6901.46	4716.20	8635.22
Total	10650.94	7511.19	18856.08	13955.02	28977.08
Profit from Operations before Other income ,Interest and Exceptional Items	2521.78	1418.58	4208.27	2521.04	4885.01
Other Income	0	0	0	0	0
Profit before Interest and Exceptional Items	2521.78	1418.58	4208.27	2521.04	4885.01
Interest	566.34	340.10	977.60	711.68	1380.26
Profit after Interest but before Exceptional Items	1955.44	1078.48	3230.67	1809.36	3504.75
Exceptional Items	0	0	0	0	0
Profit from ordinary activities before tax	1955.44	1078.48	3230.67	1809.36	3504.75
Tax Expense(Includes Deferred Tax)	389.72	183.34	810.37	266.15	775.78
Net Profit from Ordinary Activities after Tax	1565.72	895.14	2420.30	1543.21	2728.97
Extraordinary Items	0	0	0	0	0
Net Profit for the period after extra ordinary items	1565.72	895.14	2420.30	1543.21	2728.97
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	1940.00	2586.68	1940.00	1940.00
Reserves excluding Revaluation Reserves					28755.26
Earnings Per Share (EPS)					
a. Basic EPS	6.05	4.61	9.36	7.95	14.44
b. Diluted EPS	6.05	4.61	9.36	7.95	14.44
Public Shareholding					
- Number of Shares	7944924	5958690	7944924	5958690	5958690
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group					
Shareholding					
a) Pledged/Encumbered					
- Number of Shares	2721600	2508300	2721600	2508300	2721600
- % of Shares of total shareholding of promoters	15.18%	18.66%	15.18%	18.66%	20.25%
- % of Shares of total nominal capital	10.52%	12.93%	10.52%	12.93%	14.03%
b) Non-encumbered					
- Number of Shares	15200307	10933133	15200307	10933133	10719833
- % of Shares of total shareholding of promoters	84.81%	81.34%	84.81%	81.34%	79.75%
- % of Shares of total nominal capital	58.76%	56.36%	58.76%	56.36%	55.26%

NOTES :

- The above results are reviewed by the audit committee at the meeting held on 11.11.2010 and thereafter taken on record by the Board of Directors at their meeting held on 11.11.2010.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The company has opted to furnish consolidated financial results in term of Clause 41(e) (i) of Listing Agreement and the same are being furnished to the Stock Exchange separately.
- Details of Investors complaints for the quarter ended 30 th Sept, 2010
Unresolved at the beginning of the quarter - Nil, Received during the quarter - 5, Disposed off during the quarter-5
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALF OF THE BOARD




MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 11th November, 2010

Parenteral Drugs (India) Limited

Particulars	Standalone	(Rs. in Lacs)
	6 months ended	Year ended
	30-09-2010	31-03-2010
	Unaudited	Audited
SHAREHOLDERS FUND:		
(a) Capital	3825.54	3178.86
(b) Reserves and Surplus	30649.94	28876.32
LOAN FUNDS	22289.04	19928.39
FIXED ASSETS	26419.76	22596.88
INVESTMENTS	13953.35	13953.35
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	6987.94	6695.14
(b) Sundry Debtors	9741.75	10171.33
(c) Cash and Bank balances	599.63	969.39
(d) Loans and Advances and other current assets	3522.11	3712.56
Less: Current Liabilities and Provisions		
(a) Liabilities	3316.32	4439.86
(b) Provisions	1144.34	1675.86
MISCELLANEOUS EXPENDITURE	0.64	0.64
(NOT WRITTEN OFF OR ADJUSTED)		
PROFIT AND LOSS ACCOUNT	0.00	0.00
TOTAL	56764.52	51983.57



PARENTERAL DRUGS (INDIA) LIMITED
REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED ON 30 TH SEPTEMBER 2010

(Rs. In Lacs)

Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the previous period	For the Year ended
	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	31-03-2010 (Audited)
Net Sales/ Income from Operations	16227.37	8901.14	28543.18	16425.85	41445.43
Other operating Income	24.16	28.63	46.81	50.21	186.52
Total Income	16251.53	8929.77	28589.99	16476.06	41631.95
Expenditure					
- Increase / Decrease in stock in trade and work in progress	-614.86	256.18	-683.05	-453.73	-59.22
- Consumption of raw materials	8222.52	4420.51	14336.60	8809.81	22809.84
- Employees cost	523.34	305.96	976.07	592.74	1395.16
- Depreciation	231.00	145.00	461.00	290.00	902.97
- Other Expenditure	4707.38	2383.54	8278.97	4716.20	10862.04
Total	13069.38	7511.19	23369.59	13955.02	35910.79
Profit from Operations before Other income ,Interest and Exceptional Items	3182.15	1418.58	5220.40	2521.04	5721.16
Other Income	0	0	0	0	0
Profit before Interest and Exceptional Items	3182.15	1418.58	5220.40	2521.04	5721.16
Interest	654.68	340.10	1139.65	711.68	1748.16
Profit after Interest but before Exceptional Items	2527.47	1078.48	4080.75	1809.36	3973.00
Exceptional Items	0	0	0	0	0
Profit from ordinary activities before tax	2527.47	1078.48	4080.75	1809.36	3973.00
Tax Expense(Includes Deferred Tax)	507.87	183.34	988.44	266.15	928.61
Net Profit from Ordinary Activities after Tax	2019.59	895.14	3092.30	1543.21	3044.39
Extraordinary Items	0	0	0	0	0
Net Profit for the period after extra ordinary items	2019.59	895.14	3092.30	1543.21	3044.39
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	1940.00	2586.68	1940.00	1940.00
Reserves excluding Revaluation Reserves					29625.76
Earnings Per Share (EPS)					
a. Basic EPS	7.81	4.61	11.95	7.95	16.11
b. Diluted EPS	7.81	4.61	11.95	7.95	16.11
Public Shareholding					
- Number of Shares	7944924	5958690	7944924	5958690	5958690
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	2721600	2508300	2721600	2508300	2721600
- % of Shares of total shareholding of promoters	15.18%	18.66%	15.18%	18.66%	20.25%
- % of Shares of total nominal capital	10.52%	12.93%	10.52%	12.93%	14.03%
b) Non-encumbered					
- Number of Shares	15200307	10933133	15200307	10933133	10719833
- % of Shares of total shareholding of promoters	84.81%	81.34%	84.81%	81.34%	79.75%
- % of Shares of total nominal capital	58.76%	56.36%	58.76%	56.36%	55.26%

NOTES :

- The above consolidated unaudited financial results are reviewed by the audit committee at the meeting held on 11.11.2010 and thereafter taken on record by the Board of Directors at their meeting held on 11.11.2010.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The Standalone results have been filed with the Stock Exchange (s) as additional information along with the consolidated results, as per the requirement of clause 41 of the Listing Agreement.
- The Hon'ble High Court of Judicature at Bombay vide its order dated 12th October, 2009, has approved the Scheme of Amalgamation of M/s.Goa Holdings (I) Pvt.Ltd & M/s.PFL Holdings Pvt.Ltd. With the Company w.e.f. the appointed date i.e.1st November, 08. The results for the quarter ended 30.09.09 do not reflect the effect of the amalgamation and hence are not comparable .
- Standalone information:-


(Rs. In Lacs)

Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the previous period	For the Year ended
	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	30-09-2010 (Unaudited)	30-09-2009 (Unaudited)	31-03-2010 (Audited)
Total Income	13172.72	8929.77	23064.35	16476.06	33862.09
Profit Before Tax	1955.44	1078.48	3230.67	1809.36	3504.75
Profit After Tax	1565.72	895.14	2420.30	1543.21	2728.97

8. Details of Investors complaints for the quarter ended 30th September, 2010

Unresolved at the beginning of the quarter - Nil, Received during the quarter - 5, Disposed off during the quarter-5
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALF OF THE BOARD



MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 11th November, 2010

Parenteral Drugs (India) Limited

Consolidated

(Rs. in Lacs)

Particulars	6 months ended	Year ended
	30-09-2010	31-03-2010
	Unaudited	Audited
SHAREHOLDERS FUND:		
(a) Capital	3825.54	3178.86
(b) Reserves and Surplus	32246.34	29800.72
LOAN FUNDS	27074.68	25582.95
FIXED ASSETS	29636.53	25580.65
INVESTMENTS	34.10	34.10
INTANGIBLE ASSETS	13218.17	13218.17
CURRENT ASSETS, LOANS AND ADVANCES		
(a) Inventories	8107.74	8543.19
(b) Sundry Debtors	11902.72	12289.26
(c) Cash and Bank balances	786.75	1281.95
(d) Loans and Advances and other current assets	4551.38	4362.48
Less: Current Liabilities and Provisions		
(a) Liabilities	4051.75	5176.67
(b) Provisions	1380.29	1911.81
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	341.21	341.21
PROFIT AND LOSS ACCOUNT	0.00	0.00
TOTAL	63146.56	58562.53

